BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Annalisa PetrelliSabrina RizzolioFilippo PietrantonioSara Erika BellomoMatteo BenelliLoris De CeccoDario RomagnoliEnrico BerrinoClaudia OrrùSalvatore RibisiDaniel Moya-RullCristina MiglioreDaniela ConticelliIrene M MainaElisabetta PuligaVioleta SerraBenedetta PellegrinoAlba Llop-GuevaraAntonino MusolinoSalvatore SienaAndrea Sartore-BianchiMichele PrisciandaroFederica MoranoMaria AntistaUberto Fumagalli RomarioGiovanni De ManzoniMaurizio DegiuliGian Luca BaiocchiMarco F AmisanoAlessandro FerreroCaterina MarchioSimona CorsoSilvia GiordanoPublished in: Cancer research (2023)
PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended.